Weekly Market Update and Spotlight on EBOS Group Limited: Dominating Healthcare and Animal Care in Australasia.

The past week saw mostly negative movements across global indices, reflecting a cautious market sentiment influenced by various economic indicators and concerns. The NZX 50 fell by 1.66%, closing at 12,559.28, as investors responded to domestic concerns around economic growth moderation. In Australia, the All Ordinaries slipped by 1.04% to 8,379.65, impacted by weak retail data and persistent inflationary challenges, which weighed on consumer sentiment.

In the U.S., the Dow Jones edged down by 0.15% to 42,052.19. While GDP data showed robust growth, manufacturing data signalled possible slowdowns in certain sectors. The ISM Manufacturing PMI unexpectedly fell to 46.5 in October 2024 from 47.2 in September and below forecasts of 47.6. The NASDAQ dropped by 1.5%, driven by rising bond yields, which pressured tech stocks reliant on future growth projections.

The New Zealand Dollar strengthened against the Australian Dollar by 0.5%, attributed to relatively favourable economic indicators in New Zealand. However, it weakened against the U.S. Dollar by 0.38%, reflecting the dollar’s resilience as investors anticipate gradual U.S. rate cuts.

Weekly Market Movers


Source: Iress

Investment News: Staying Focused During Election Season
With the upcoming election, we’re here to help you navigate how potential changes could impact your financial plans—without diving into political predictions. Election cycles can bring market volatility due to policy uncertainty and investor sentiment. Staying focused on your long-term goals can help mitigate these fluctuations.

Spotlight on EBOS Group Limited: Dominating Healthcare and Animal Care in Australasia

EBOS Group Limited, with a market capitalisation of NZD 6.98 billion, is a major

 player in the healthcare and animal care distribution sectors across Australasia. Listed on the NZX 50 with a 4.86% weighting, EBOS provides an extensive range of products and services, from pharmaceutical and medical consumables to veterinary products, catering to hospitals, pharmacies, clinics, and veterinary centers. Founded as Early Bros Dental & Surgical Supplies Ltd. in 1922 and rebranded to EBOS Group in 1986, the company has evolved into a healthcare distribution powerhouse, securing a solid reputation for both growth and reliability.

Strategic Initiatives and Market Position

EBOS’s strength lies in its dual focus on the healthcare and animal care markets. In healthcare, it provides medication management, logistics, and software solutions to pharmacies and healthcare facilities. Programmes like Pharmacy Choice and healthSAVE help independent pharmacies enhance their retail operations, while EBOS’s hospital supplies business serves both public and private healthcare institutions, from day surgeries to aged care facilities. The company’s diverse offerings in healthcare logistics and consumables make it an essential supplier in the region.

In the animal care sector, EBOS distributes pet nutrition, grooming products, and veterinary supplies for companion animals, livestock, and equine athletes, capitalising on the growing demand for pet healthcare. The animal care market has been a high-growth segment for EBOS, driven by increased pet ownership and spending on pet health products.

Fundamental Analysis

Current Valuation and Price Target

EBOS currently trades at NZD 36.00 with a target price of NZD 38.51, presenting an upside potential of approximately 6.97%. Over the past five years, the company has delivered an annualised historical return of 10.99%, highlighting its resilience and consistent growth. The company’s risk profile, with a five-year historical standard deviation of 23.97%, is reasonable given its steady financial performance and strategic positioning within a relatively stable sector.

Financial Forecast and Growth Prospects

EBOS’s forecasted financial metrics illustrate promising growth over the coming years:
Revenue: Revenue is projected to increase from NZD 14,473 million in FY2024 to NZD 14,210 million by FY2027. This steady growth is expected to be driven by continued expansion in both the healthcare and animal care segments, as well as strategic acquisitions and partnerships.

EBITDA: Expected to reach NZD 748 million by FY2027, EBITDA growth reflects the company's focus on enhancing operational efficiencies and expanding its market share. EBOS’s EBITDA margins have steadily improved, supporting profitability as it scales its business.

Net Debt: Net debt is projected to decrease from NZD 1,118 million in FY2024 to NZD 952 m

illion by FY2027, illustrating EBOS’s commitment to financial stability and prudent capital management. This deleveraging trajectory is favourable for long-term investors, enhancing EBOS’s ability to pursue growth initiatives without overextending its balance sheet.

Profitability and Valuation Ratios

EBOS demonstrates solid profitability ratios, making it an attractive option for value-seeking investors:

PE Ratio: Expected to decline from 20.66 in FY2024 to 18.65 by FY2027, EBOS’s valuation is becoming increasingly attractive, reflecting investor confidence in its growth potential at a reasonable price.

Dividend Yield: EBOS’s dividend yield is expected to grow slightly from 3.63% to 3.79%, rewarding shareholders with consistent income. This is especially appealing for income-focused investors who are looking for steady dividends from companies with a strong market position.

Return on Equity (ROE): EBOS boasts a healthy ROE of 11.57% in FY2024, reflecting effective management and profitability. Its return on assets (ROA) and return on capital (ROC) are also solid, underscoring its efficient use of assets to generate earnings.

Growth and Profitability Trends

In the broader context of growth, EBOS has shown impressive performance metrics:

Revenue and Net Income Growth: Over a five-year period, total revenue has grown by an annualised 13.73%, while net income growth has averaged 13.75%, highlighting EBOS’s sustained ability to drive sales and profitability in a competitive market.

Gross Margin: EBOS has improved its gross margin from 10.7% in 2021 to 12.38% in 2024, demonstrating effective cost management and operational efficiencies.

These growth trends and profitability improvements indicate that EBOS has successfully navigated the challenges of scaling its business, optimising its supply chains, and capturing new market opportunities.

Investment Considerations

For investors, EBOS represents a balanced blend of growth and stability:
Consistent Revenue Growth: EBOS’s revenue and earnings growth reflect a resilient business model that has adapted to sector demands and captured growth opportunities.

Attractive Dividend Yield: A growing dividend yield, coupled with a stable financial structure, provides reliable income for dividend-seeking investors.

Strong Market Position: As one of the leading healthcare distributors in Australasia, EBOS’s established market presence reduces risk, while its focus on both healthcare and animal care offers a diversified revenue base.

Improving Financial Health: EBOS’s declining net debt and consistent cash flow growth enhance its ability to finance future growth initiatives and return capital to shareholders.

Conclusion

EBOS Group Limited’s robust fundamentals, strategic market position, and disciplined growth strategy make it a compelling investment opportunity in the healthcare and animal care sectors. With a steadily improving financial profile, an attractive dividend yield, and consistent growth in revenue and EBITDA, EBOS is well-suited for investors seeking both capital appreciation and income. As always, investors should consider both the growth potential and associated risks, including sector-specific challenges and economic factors, when evaluating EBOS as part of a diversified portfolio. In summary, EBOS’s solid financial performance, attractive valuation, and strategic market positioning make it an appealing option for investors looking to gain exposure to the healthcare and animal care markets in Australasia.


Upcoming Dividends: 5th November to 5th December.

Source: Iress

---
For more information and to stay updated subscribe to our newsletter and consult with your Financial Adviser to tailor your investment strategy.

Disclaimer: “Yovich & Co Limited believes the information in this publication is correct, and it has reasonable grounds for any opinion or recommendation found within this publication on the date of this publication. However, no liability is accepted for any loss or damage incurred by any person as a result of any error in any information, opinion or recommendation in this publication. Nothing in this publication is, or should be taken as, an offer, invitation or recommendation to buy, sell or retain any investment in or make any deposit with any person. The information contained in this publication is general in nature. It may not be relevant to individual circumstances. Before making any investment, insurance or other financial decisions, you should consult a professional financial adviser. This publication is for the use of persons in New Zealand only. Copyright in this publication is owned by Yovich & Co Limited. You must not reproduce or distribute content from this publication or any part of it without prior permission.